EMEA-003085-PIP01-21 - paediatric investigation plan

sibeprenlimab

Key facts

• Active substance:
  sibeprenlimab
• Therapeutic area:
  Uro-nephrology
• Decision number:
  P/0232/2022
• PIP number:
  EMEA-003085-PIP01-21
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of primary immunoglobulin A nephropathy
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  08/07/2022
• Compliance check done:
  No

Decision

P/0232/2022: EMA decision of 8 July 2022 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for sibeprenlimab (EMEA-003085-PIP01-21)

Adopted Reference Number: EMA/575972/2022